Laurence Greenbaum, MD
Pediatric Nephrology · Atlanta, GANPI 1447278742
Payments from drug & device makers
Across 244 payments — averaging $6672.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$554K
- AstraZeneca$257K
- Genentech, Inc.$245K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$150K
- Apellis Pharmaceuticals, Inc.$81K
- Aurinia Pharma U.S., Inc.$61K
- plus $281K from 16 others
Across 11 payments — averaging $1006.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$6K
- Novartis Pharma AG$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$68
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 20 | $553,879 |
| AstraZeneca | 102 | $257,076 |
| Genentech, Inc. | 18 | $244,930 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 15 | $149,796 |
| Apellis Pharmaceuticals, Inc. | 13 | $80,789 |
| Aurinia Pharma U.S., Inc. | 2 | $60,649 |
| Novo Nordisk US Research & Development, Inc. | 12 | $54,836 |
| Amgen | 1 | $47,326 |
| Novartis | 6 | $46,368 |
| AbbVie | 2 | $31,150 |
| Travere Therapeutics, Inc. | 32 | $30,326 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 3 | $15,528 |
| Novo Nordisk AS | 1 | $8,976 |
| E.r. Squibb & Sons, L.L.C. | 2 | $7,992 |
| Samsung Bioepis Co., Ltd. | 3 | $7,328 |
| Vifor Pharma, Inc. | 2 | $6,600 |
| F. Hoffmann-la Roche AG | 2 | $5,320 |
| Alnylam Pharmaceuticals Inc. | 3 | $4,800 |
| Akebia Therapeutics Inc | 1 | $4,500 |
| Biogen | 2 | $3,638 |
| Roche Products Limited | 1 | $3,220 |
| Leadiant Biosciences, Inc. | 1 | $3,000 |
How this compares
Too few pediatric nephrology providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric nephrology in Atlanta
- Chia-Shi WangAtlanta$278K
- Stephanie JerniganAtlanta$119K
- Sabina KennedyAtlanta$56K
- Rouba GarroAtlanta$9K
- Jacob HumphreyAtlanta$119
- Pamela WinterbergAtlanta$74
- Barry WarshawAtlanta$4
- Asifhusen MansuriAugusta$28K
- Luis OrtizAugusta$948
- Heather StewartSavannah$579
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.